Precipio, Inc. (PRPO) Stock Price & Analysis
Precipio, Inc. (PRPO) closed at USD 20.01 on Friday, October 23, 2026, down 2.91% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 20.61; the Oct 23, 2026 session ranged USD 20–20.65 on volume of 11,193 shares. Market capitalization is $35.82M, with a 52-week range of USD 18.5–33.63 (NCM). Source: Nexqual, retrieved October 24, 2026 at 12:40 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PRPO.md
Key facts (PRPO)
- Last four reported quarters (through Jun 30, 2026): revenue $27.7M, net income -$1.2M (-4.4% margin), free cash flow $789K (SEC filings).
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $100K; 2 not under a Rule 10b5-1 plan ($100K); 2 by opportunistic insiders (2 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $1K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: None.
- Total return with dividends: 1Y -2.6% vs S&P 500 +13.4%; 5Y -57.6% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PRPO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | $9.8M | $15.4M | $18.6M | $24.2M | $27.7M |
| Gross profit | $2.4M | $2.5M | $6.0M | $7.6M | $10.7M | — |
| Operating income | -$9.6M | -$12.8M | -$7.6M | -$4.2M | -$1.2M | -$1.5M |
| Net income | -$8.5M | -$12.2M | -$5.9M | -$4.3M | -$363K | -$1.2M |
| EPS (diluted) | -$8.00 | -$10.73 | -$4.51 | -$2.93 | -$0.23 | — |
| Free cash flow | -$7.3M | -$8.0M | -$3.7M | $216K | $359K | $789K |
| Gross margin | 27.0% | 25.6% | 39.0% | 40.7% | 44.2% | — |
| Operating margin | -108.6% | -130.3% | -49.4% | -22.7% | -5.0% | -5.6% |
| Net margin | -96.2% | -124.0% | -38.0% | -23.1% | -1.5% | -4.4% |
| Revenue growth | +19.1% | +11.0% | +57.0% | +20.5% | +30.5% | — |
| Cash + short-term investments | $11.7M | $3.4M | $1.5M | $1.4M | $2.7M | — |
| Total debt | $186K | $404K | $353K | $383K | $83K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PRPO)
P/S 1.3x · EV/Sales 1.2x · P/FCF 45.4x · P/B 2.4x · FCF yield 2.20% · Earnings yield -3.39% · Net cash $2.8M · EV $33.1M
Insider sales (SEC Form 4, open-market, last ~7 months) (PRPO)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | Sandberg Richard A | Director | 900 | $23K | 2.4% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-19…2026-05-20 | Sandberg Richard A | Director | 3,134 | $78K | 7.8% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (PRPO)
1 purchase, $1K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-04-01 | Sabet Ahmed Zaki | Chief Operating Officer | 19 | $1K | 27.93 | Too little history (no open-market trades in 2024) |
Analysts (PRPO)
Consensus None.
Total return (dividends reinvested) (PRPO)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -2.6% | -57.6% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -2.6% | -15.8% |
| Volatility (annualized) | 60.4% | 66.2% |
| Max drawdown | -38.2% (May 2026→Oct 2026) | -90.1% (Oct 2021→Jul 2024) |
PRPO revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Service Revenue Net | $6.1M | 87.1% | +22.2% |
| Product | $906,000 | 12.9% | +45.2% |
| Total revenue | $7.0M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
PRPO customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 30% of revenue, per the company's 10-Q filed Aug 14, 2026. The company does not name it.
PRPO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends Mar 2024) | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2023) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 12:40 UTC)
| Price | USD 20.01 |
|---|---|
| Change | ▼ 2.91% (down) |
| Previous Close | USD 20.61 |
| Open | USD 20.57 |
| Day Range | USD 20 – 20.65 |
| 52-Week Range | USD 18.5 – 33.63 |
| Volume | 11,193 shares |
| Market Cap | $35.82M |
| Exchange | NCM |
Technical Analysis (PRPO)
Nexqual's technical model rates PRPO "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 12:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.49 (oversold) |
| vs SMA50 | Below (USD 25.28) |
| MACD | -1.19 (negative) |
Analyst Ratings (PRPO)
Wall Street analysts rate PRPO "None", per Nexqual as of October 24, 2026 at 12:40 UTC.
| Consensus Rating | None |
|---|
Earnings (PRPO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -1.04 vs est -1.4 ▲ beat |
| 2023-06-30 | USD -1.8 vs est -2 ▲ beat |
| 2023-03-31 | USD -2.6 vs est -2.6 ▲ beat |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Financials & Fundamentals (PRPO)
| Total Revenue | $27.20M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +24.20% |
| Gross Margin | +44.11% |
| Operating Margin | -8.53% |
| Profit Margin | -4.47% |
| ROE | -8.98% |
| Debt / Equity | 0.24 |
| Current Ratio | 1.77 |
| Total Cash | $3.08M |
| Total Debt | $3.59M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $789,000 (2.8% of revenue) |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Financial Health Score (PRPO)
Nexqual rates Precipio, Inc.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 12:40 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $3M cash and investments, no debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $789K (last 4 quarters to Jun 2026, SEC), slim 2.8% margin |
| Efficiency | Critical — ROE -9%, ROA -4.8% |
Ownership (PRPO)
| Insider Ownership | +12.67% |
|---|---|
| Institutional Ownership | +17.78% |
| Shares Outstanding | 1.79M |
| Float | 1.41M |
| Short % of Float | +4.22% |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Leadership (PRPO)
Precipio, Inc. is led by Ilan Danieli, Founder, President, CEO & Director, per Nexqual as of October 24, 2026 at 12:40 UTC.
| Founder, President, CEO & Director | Ilan Danieli |
|---|---|
| Chief Operating Officer | Ahmed Zaki Sabet |
| Chief Technology Officer | Ayman A. Mohamed |
| Chief Financial Officer | Matthew Gage |
Major Backers & Investors (PRPO)
Notable institutional backers of Precipio, Inc. include Renaissance Technologies, Citadel, Fidelity, according to Nexqual as of October 24, 2026 at 12:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 0.9% |
| Citadel | 0.82% |
| Fidelity | 0.77% |
| Xtx Topco Ltd | 0.53% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Micro Cap Portfolio | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.11% |
| BlackRock | 1.94% |
| Geode Capital | 1.04% |
| Dimensional Fund Advisors | 0.47% |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
From Precipio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- If the FDA determines that a manufacturer has failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, including the following: Currently, we offer our products as RUO products.
- Historically, it has been the FDA's position that it has exercised enforcement discretion with respect to most LDTs and has not required laboratories that offer LDTs to comply with the FDA's requirements for medical devices, such as the FDA's requirements pertaining to marketing authorization, establishment registration, device listing, the Quality System Regulation (as of February 2, 2026, the Quality Management System Regulation), and other post-market controls.
- The GDPR also imposes strict rules on the transfer of personal data to countries outside of the UK and EEA that do not ensure an adequate level of protection, including the United States in certain circumstances, unless derogation exists or a valid GDPR transfer mechanism (for example, the European Commission approved Standard Contractual Clauses (SCCs) and the UK International Data Transfer Agreement or Addendum (UK IDTA) have been put in place, and transfer impact assessments conducted).
- We own pending U.S. and European patent applications on our proprietary panels.
Legal & Regulatory Risks (Item 1A, quoted)
- We believe that we are in compliance with all applicable laboratory requirements, but no assurances can be given that our laboratories will pass all future certification inspections.
- Our products that we sell as research use only products and/or that we offer as laboratory developed tests could become subject to government regulations requiring marketing authorization, and the marketing authorization and maintenance process for such products may be expensive, time-consuming and uncertain in both timing and outcome.
- Our failure to comply with any applicable government laws and regulations or otherwise respond to claims relating to improper handling, storage or disposal of hazardous chemicals that we use may adversely affect our results of operations.
- We may become subject to the Anti-Kickback Statute, Stark Law, False Claims Act, Civil Monetary Penalties Law and may be subject to analogous provisions of applicable state laws and could face substantial penalties if we fail to comply with such laws.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FLGT | Fulgent Genetics, Inc. | USD 20.1 | ▲ 0.55% |
| MYGN | Myriad Genetics, Inc. | USD 5.82 | ▲ 1.04% |
| CSTL | Castle Biosciences, Inc. | USD 33.08 | ▼ 0.33% |
| OPK | Opko Health, Inc. | USD 1.63 | ▲ 0% |
| FRNM | Freenome, Inc. | USD 12.77 | ▼ 2.52% |
| WGS | GeneDx Holdings Corp. | USD 56.15 | ▼ 16.37% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt